. Faergemann J, Todd G, Pather S, et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol. 2009 Dec. 61(6):971-6. [QxMD MEDLINE Link]. 51. Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg
. Faergemann J, Todd G, Pather S, et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol. 2009 Dec. 61(6):971-6. [QxMD MEDLINE Link]. 51. Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg
. Pramiconazole and sertaconazole have also been used in the management of tinea versicolor. [49, 50] A review suggested the following dosing regimens: 200 mg/d for 5 or 7 days of itraconazole, 300 mg/wk for 2 weeks of fluconazole, and 200 mg/d for 2 days of pramiconazole. [51] Oral therapy does not prevent the high rate of recurrence, and treatment with an oral or topical agent may need to be repeated Med J. 2010 Jan. 19(1):72-6. [QxMD MEDLINE Link]. 50. Faergemann J, Todd G, Pather S, et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol. 2009 Dec. 61(6):971-6. [QxMD MEDLINE Link]. 51. Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea
. Pramiconazole and sertaconazole have also been used in the management of tinea versicolor. [49, 50] A review suggested the following dosing regimens: 200 mg/d for 5 or 7 days of itraconazole, 300 mg/wk for 2 weeks of fluconazole, and 200 mg/d for 2 days of pramiconazole. [51] Oral therapy does not prevent the high rate of recurrence, and treatment with an oral or topical agent may need to be repeated Med J. 2010 Jan. 19(1):72-6. [QxMD MEDLINE Link]. 50. Faergemann J, Todd G, Pather S, et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol. 2009 Dec. 61(6):971-6. [QxMD MEDLINE Link]. 51. Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea
Absence of an active metabolite for the triazole antifungal pramiconazole. Pramiconazole is an antifungal with high potential for the treatment of dermatophyte and yeast infections of the skin. It is currently not known whether pramiconazole is active alone as the parent agent or assisted by active metabolites. The in vitro metabolism as well as the metabolic stability of pramiconazole was investigated in subcellular liver fractions and isolated hepatocytes of several species. Results indicate that the metabolism of pramiconazole was slow, since the enzyme-mediated disappearance of pramiconazole was rather slow. To investigate whether pramiconazole was converted into an active metabolite in humans, serum samples from healthy volunteers receiving a daily dose of 100 or 200 mg pramiconazole
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models. The triazole antifungal pramiconazole (Stiefel, a GSK company) was compared with itraconazole, miconazole, and terbinafine in vitro and in vivo. Potent in vitro activities against Candida spp. (50% inhibitory concentration [IC₅₀], 0.04 to 1.83 μM ) and Microsporum and Trichophyton spp. (IC₅₀, 0.15 to 1.34 μM) were obtained but not, however, against other filamentous molds and zygomycetes. In the M. canis guinea pig model and C. albicans vulvovaginitis rat model, pramiconazole was superior to the reference compounds after oral and topical administration.
A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. Pramiconazole is a broad-spectrum triazole antifungal with potential for oral treatment of pityriasis versicolor. We sought to assess the efficacy and tolerability of 5 doses of pramiconazole relative to placebo. This was a randomized, multicenter, double-blind , placebo-controlled, 28-day, dose-finding study. A total of 147 patients were randomized to treatment with placebo or one of 5 doses of pramiconazole; treatment lasted for 3 consecutive days. Efficacy was based on mycological response, severity of clinical signs and symptoms, and the Investigator Global Assessment of lesion clearance. A statistically significant (P < .001) dose-dependent effect